Clinical Trial Update: ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients [Phase 2]

View source ↗

Summary

Phase 2 study evaluating paritaprevir/ritonavir with ombitasvir and with or without dasabuvir (± ribavirin) in genotype 1 hepatitis C patients; results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Dasabuvir (dasabuvir)
• Ombitasvir (ombitasvir)
• Paritaprevir (paritaprevir)
• Ribavirin (ribavirin)
• Ritonavir (Ritonavir)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Chronic Hepatitis C, Hepatitis C (HCV) | Phase 2 | Status: COMPLETED | Results posted: 2015-01-06